VTGN - VistaGen: Phase 2 Success In Anxiety Disorder Phase 3 To Begin April, 25 2021 08:00 AM VistaGen Therapeutics Inc. VistaGen has had a tumultuous history, but recent trials have seen success. They may start phase 3 trials for PH94B in May. Dilution is a major risk. For further details see: VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin